TapewireFind a company

person · Reporting owner

Kelly John Alexander

Disclosed activity across 1 company

Tapewire entity
41657
SEC CIK
0001590030

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PRECISION BIOSCIENCES INCDTIL · Entity 6284Chief Financial OfficerJune 01, 2026June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PRECISION BIOSCIENCES INC

Report date June 01, 2026 · Filed June 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect193,688 Reported balance After 2026-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-01 · Grant · Acquired 193,688 · Balance 193,688

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 01, 2026 Filed Jun 3, 2026 20:05 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 193,688 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-040215 · wk-form4_1780517141.xml · derivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,688

Underlying: Common Stock · 193,688 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 18, 2026 Filed Feb 19, 2026 21:31 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 8,149 $3.84 $31,292.16
Disclosure

SEC source: 0001628280-26-009803 · wk-form4_1771536658.xml · nonDerivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,883

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:31 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 27,584 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-009803 · wk-form4_1771536658.xml · derivative · entry 3

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,166

Underlying: Common Stock · 27,584 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 21:31 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 27,584 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-009803 · wk-form4_1771536658.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 21, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 15,213 $4.03 $61,308.39
Disclosure

SEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 4

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,448

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 26,575 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · derivative · entry 7

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,575

Underlying: Common Stock · 26,575 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 13,900 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · derivative · entry 6

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,901

Underlying: Common Stock · 13,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 3,888 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · derivative · entry 5

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,888 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 26,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 3

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,661

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 13,900 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,086

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 23:48 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 3,888 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 03, 2025 Filed Nov 4, 2025 21:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 1,303 $6.49 $8,456.47
Disclosure

SEC source: 0001628280-25-048858 · wk-form4_1762290943.xml · nonDerivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,298

F4 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Read SEC document
November 02, 2025 Filed Nov 4, 2025 21:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 3,605 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-048858 · wk-form4_1762290943.xml · derivative · entry 3

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,605 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025.

F5 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025.

Read SEC document
November 02, 2025 Filed Nov 4, 2025 21:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 3,605 $0.00 $0.00
Disclosure

SEC source: 0001628280-25-048858 · wk-form4_1762290943.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: Includes 1,511 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a price of $4.17

Read SEC document
July 03, 2025 Filed Jul 8, 2025 20:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 SaleCommon Stock 14,827 $4.26 $63,163.02
Disclosure

SEC source: 0001628280-25-034531 · wk-form4_1752006603.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,485

F1 · shares: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the settlement of 44,368 RSUs which vested on January 20, 2025. The settlement occurred on July 3, 2025, as approved by the Issuer's Compensation Committee. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F2 · balance_after: Includes 2,056 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price of $7.21.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 82,750 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-081720 · ownership.xml · derivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,750

Underlying: Common Stock · 82,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
March 03, 2025 Filed Mar 6, 2025 00:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 1,702 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034006 · ownership.xml · derivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,702 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On March 3, 2022, the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025.

F3 · derivative.expiration_date: On March 3, 2022, the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025.

Read SEC document
March 03, 2025 Filed Mar 6, 2025 00:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 1,702 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034006 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on March 3, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 26,575 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008012 · ownership.xml · derivative · entry 4

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,150

Underlying: Common Stock · 26,575 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 13,904 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008012 · ownership.xml · derivative · entry 3

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,801

Underlying: Common Stock · 13,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 3,889 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-008012 · ownership.xml · derivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,888

Underlying: Common Stock · 3,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2025 Filed Jan 23, 2025 02:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 44,368 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-008012 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,554

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
December 27, 2024 Filed Dec 31, 2024 12:00 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 PurchaseCommon Stock 2,113 $4.75 $10,036.75
Disclosure

SEC source: 0000950170-24-141308 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,186

Read SEC document
November 21, 2024 Filed Nov 21, 2024 21:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 PurchaseCommon Stock 3,000 $6.76 $20,280.00
Disclosure

SEC source: 0000950170-24-129735 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,073

Read SEC document
November 02, 2024 Filed Nov 6, 2024 00:14 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 3,605 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-121729 · ownership.xml · derivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,605

Underlying: Common Stock · 3,605 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
November 02, 2024 Filed Nov 6, 2024 00:14 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 3,605 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-121729 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on November 2, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 22, 2024 Filed Aug 23, 2024 11:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 79,725 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-100020 · ownership.xml · derivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,725

Underlying: Common Stock · 79,725 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
June 07, 2024 Filed Jun 11, 2024 21:13 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 454 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-072050 · ownership.xml · derivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 454 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024.

F3 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024.

Read SEC document
June 07, 2024 Filed Jun 11, 2024 21:13 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 454 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-072050 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,468

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
May 08, 2024 Filed May 9, 2024 00:26 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 8,334 $12.00 $100,008.00
Disclosure

SEC source: 0000950170-24-056140 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,014

F1 · shares: Represents shares purchased through a definitive subscription agreement, pursuant to which the Issuer agreed to issue and sell shares of its common stock in a non-brokered private placement to certain members of its management.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:34 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 1,702 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-053116 · ownership.xml · derivative · entry 3

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,702

Underlying: Common Stock · 1,702 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:34 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 1,702 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-053116 · ownership.xml · nonDerivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,680

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Represents the partial vesting of Restricted Stock Units ("RSUs") on March 3, 2024, and subsequent settlement of such vested RSUs on May 1, 2024.

F3 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
April 18, 2024 Filed Apr 23, 2024 01:12 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 41,705 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-046596 · ownership.xml · derivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,705

Underlying: Common Stock · 41,705 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 29, 2024 Filed May 3, 2024 22:34 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 506 $18.50 $9,361.00
Disclosure

SEC source: 0000950170-24-053116 · ownership.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,978

F1 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split.

Read SEC document
January 20, 2024 Filed Jan 24, 2024 00:19 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 116,690 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-002121 · doc4.xml · derivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233,310

Underlying: Common Stock · 116,690 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F3 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
January 20, 2024 Filed Jan 24, 2024 00:19 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 116,690 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-002121 · doc4.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 614,169

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
November 02, 2023 Filed Nov 6, 2023 22:04 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 108,188 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-054546 · doc4.xml · derivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,312

Underlying: Common Stock · 108,188 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F3 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
November 02, 2023 Filed Nov 6, 2023 22:04 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 108,188 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-054546 · doc4.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 497,479

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
August 31, 2023 Filed Sep 5, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 5,951 $0.39 $2,320.89
Disclosure

SEC source: 0001209191-23-048144 · doc4.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 389,291

F1 · kind: These shares were acquired under the Issuer's 2019 Employee Stock Purchase Plan subsequent to the Reporting Person's Form 4 filed on August 22, 2023.

Read SEC document
August 18, 2023 Filed Aug 22, 2023 20:10 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 90,000 $0.48 $43,200.00
Disclosure

SEC source: 0001209191-23-046874 · doc4.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 383,340

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.47 to $0.485. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
August 18, 2023 Filed Oct 27, 2023 20:55 UTC Amendment PRECISION BIOSCIENCES INC DTIL · Entity 6284 PurchaseCommon Stock 90,000 $0.48 $43,200.00
Disclosure

SEC source: 0001209191-23-053784 · doc4a.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 383,340

F1 · kind: This amendment is being filed to correct the Transaction Code (as set forth in Box 3). The Form 4, as originally filed, inadvertently reported the Transaction Code as "A."

F2 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.47 to $0.485. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 13,635 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-035792 · doc4.xml · derivative · entry 4

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,635

Underlying: Common Stock · 13,635 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F4 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 34,091 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-035792 · doc4.xml · derivative · entry 3

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,091 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F3 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in two substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in two substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 13,635 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-035792 · doc4.xml · nonDerivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 293,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:15 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 34,091 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-035792 · doc4.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,705

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

Read SEC document
March 17, 2023 Filed Mar 21, 2023 13:19 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 PurchaseCommon Stock 20,000 $0.86 $17,200.00
Disclosure

SEC source: 0001209191-23-020154 · doc4.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,614

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.847 to $0.87. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 22:08 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionRestricted Stock Units · Derivative 51,071 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016835 · doc4.xml · derivative · entry 3

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,114

Underlying: Common Stock · 51,071 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F3 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 22:08 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 Exercise / conversionCommon Stock 51,071 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016835 · doc4.xml · nonDerivative · entry 2

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 3, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
February 28, 2023 Filed Mar 7, 2023 22:08 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantCommon Stock 11,605 $0.95 $11,024.75
Disclosure

SEC source: 0001209191-23-016835 · doc4.xml · nonDerivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,543

Read SEC document
January 20, 2023 Filed Jan 24, 2023 21:30 UTC PRECISION BIOSCIENCES INC DTIL · Entity 6284 GrantRestricted Stock Units · Derivative 350,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004610 · doc4.xml · derivative · entry 1

Kelly John Alexander · CIK 0001590030 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.